| Dosing |
Adult usual dosage: Glaucoma, open-angle: Initial, 250 mg QD-QID. Glaucoma, secondary or preoperative treatment to reduce intraocular pressure: 250 mg BID to Q4H, or 500 mg initial dose followed by 125 or 250 mg every 4 hours. Epilepsy: 8-30 mg/kg daily in divided doses, optimum range: 375-1000 mg daily. Edema: 5 mg/kg (usual dosage: 250 to 375 mg) QD in the morning for 1 or 2 days, alternating with a day of rest. [Micromedex 2021/06/17] Acute mountain sickness; Treatment and Prophylaxis: 500-1000 mg daily, in divided doses; during rapid ascent, 1000 mg/day is recommended; initiate 24-48 hours before ascent and continue for 48 hours or longer while at high altitude. Pediatric usual dosage: Glaucoma: 8-30 mg/kg (usual dosage: 10-15 mg/kg) or 300-900 mg/m2 daily in divided doses. Epilepsy: 8-30 mg/kg daily in divided doses. Edema: 5 mg/kg or 150 mg/m2 QD in the morning for 1 or 2 days, alternating with a day of rest. |
| Adverse Effects |
Frequency not defined: Flushing, Allergic skin reaction, skin photosensitivity, Electrolyte disorder, glycosuria, hyperglycemia, hypoglycemia, hypokalemia, hyponatremia, Decreased appetite, diarrhea, dysgeusia, melena, nausea, vomiting, Crystalluria, hematuria, Immune thrombocytopenia, leukopenia, Abnormal hepatic function tests, cholestatic jaundice, fulminant hepatic necrosis, hepatic insufficiency, Pain at injection site, Ataxia, confusion, depression, dizziness, drowsiness, excitement, fatigue, flaccid paralysis, headache, malaise, Auditory disturbance, tinnitus, Polyuria, Fever. Postmarketing: Acute generalized exanthematous pustulosis, maculopapular rash, Stevens-Johnson syndrome, toxic epidermal necrolysis, urticaria, Growth retardation (children), metabolic acidosis, Agranulocytosis, aplastic anemia, thrombocytopenia, Anaphylaxis, Drug reaction with eosinophilia and systemic symptoms, Paresthesia , Acute angle-closure glaucoma, choroidal effusion, myopia, Renal failure syndrome. |